Fair Value Calculator Fair Value Calculator
EN DE

DME (DME) Fair Value & Analysis

Basic Materials · Market cap A$12.6M

D DME DME · AU
PriceA$0.0400
Fair ValueA$0.0320
Upside-20.0%
Quality30/100
Watch DME for free — get notified when fair value or trend changes. Watch for free
Evidence: Low Range A$0.0280 – A$0.0320

Fair value as of: Jun 26, 2026

From 3 valuation models · updated 6 days ago

Fair value updated Jun 26, 2026 — revised from A$0.0200 to A$0.0320 (+60.0%) since Jun 25, 2026. Share price +24.2% over the past month.

Price vs Fair Value (12 months)

A$0.1805 A$0.0283 Fair Value A$0.0320 Jun 2025 Jul 2026

12‑month range A$0.0283 – A$0.1805 · fair‑value band A$0.0280 – A$0.0320 · the A$0.0400 price screens above the A$0.0320 fair value. As of Jun 26, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

DME (DME) currently trades at A$0.0400, while our model-based Fair Value estimate is A$0.0320 — implying the stock looks roughly 20.0% overvalued today. We read business quality at 30/100 (below-average quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

Trailing-twelve-month revenue stands at A$9.1K. It earns a return on equity of -13.2%. Fundamentals as of Jun 26, 2026

Key figures & financial health

Revenue (TTM) A$9.1K
Revenue growth (YoY) +430%
Return on equity -13.2%
Free cash flow −A$2.8M FY2025
EPS (TTM) A$-0.0100
Net cash A$134K FY2025

Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

DME reported revenue of A$4.2K in FY2025 versus A$2.5K in FY2021, a compound +14.4%/yr. Reported net income was −A$4.6M in FY2025.

Revenue +14.4%/yr
FY21 A$2.5K
FY22 A$1.7K
FY23 A$9.1K
FY24 A$1.1K
FY25 A$4.2K
Net income
FY21 −A$2.2M
FY22 −A$2.0M
FY23 −A$3.0M
FY24 −A$2.2M
FY25 −A$4.6M

Is DME fairly valued? → Check now

Similar stocks

6 more Other Industrial Metals & Mining stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).

Stock Price Fair Value vs Fair Value
BHP Group BHP $82.95 $47.52 -43%
Rio Tinto Group RTNTF $129.57 $76.59 -41%
RIO RIO A$179.44 A$99.42 -45%
Grupo México, S.A. GMBXF $12.66 $9.58 -24%
CMOC Group CMCLY $148.88 $120.33 -19%
Vale S.A VALEN 260.19 MXN 9.30 MXN -96%

Explore undervalued stocks

More undervalued Basic Materials stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is DME (DME) undervalued?
As of Jun 26, 2026, our model estimates a fair value of A$0.0320 versus a price of A$0.0400 — about −20% (overvalued). Model-based estimate, not financial advice.
What is the fair value of DME?
Our model-based fair value for DME is A$0.0320 (as of Jun 26, 2026), built from audited fundamentals. The current price is A$0.0400.
What is the quality score of DME?
DME has a Quality Score of 30/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of DME (DME)?
DME reported trailing-twelve-month revenue of about A$9.1K (latest available figure, as of Jun 26, 2026).
What is the net profit margin of DME?
The net profit margin of DME is about 0.0%, meaning it keeps roughly 0.0% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.